Valeria Pittalà
University of Catania
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Valeria Pittalà.
Journal of Medicinal Chemistry | 2008
Maria A. Siracusa; Loredana Salerno; Maria N. Modica; Valeria Pittalà; Giuseppe Romeo; Maria E. Amato; Mateusz Nowak; Andrzej J. Bojarski; Ilario Mereghetti; Alfredo Cagnotto; Tiziana Mennini
A series of new compounds containing a benzimidazole, benzothiazole, or benzoxazole nucleus linked to an arylpiperazine by different thioalkyl chains was prepared. They were tested in radioligand binding experiments to evaluate their affinity for 5-HT 1A and 5-HT 2A serotonergic, alpha 1 adrenergic, D1, and D2 dopaminergic receptors. Many of tested compounds showed an interesting binding profile; in particular, 36 displayed very high 5-HT 1A receptor affinity and selectivity over all the other investigated receptors. Selected compounds, evaluated in functional assays, showed antagonistic or partial agonistic activity at 5-HT 1A receptor. An extensive conformational research using both NMR and modeling techniques indicated that extended conformations predominated in vacuum, in solution and during interactions with 5-HT 1A receptor. Finally, the elaborated binding mode of selected compounds at 5-HT 1A receptor was used to explain the influence of spacer length on ligands affinity.
Mini-reviews in Medicinal Chemistry | 2007
Valeria Pittalà; Loredana Salerno; Maria N. Modica; Maria A. Siracusa; Giuseppe Romeo
The 5-HT(7) receptors (5-HT(7)Rs) are the most recent classified members of the serotonin family. Characterized in 1993, they belong to the G protein-coupled receptor family. Since their discovery, they have been the subject of intense research due to their widespread distribution in the brain, suggestive of multiple central roles. The focus of this review is to discuss the literature concerning recent advances on 5-HT(7)Rs and their ligands.
Bioorganic & Medicinal Chemistry | 2013
Loredana Salerno; Valeria Pittalà; Giuseppe Romeo; Maria N. Modica; Maria A. Siracusa; Claudia Di Giacomo; Rosaria Acquaviva; Ignazio Barbagallo; Daniele Tibullo; Valeria Sorrenti
A novel series of aryloxyalkyl derivatives of imidazole and 1,2,4-triazole, 17-31, was designed and synthesized as inhibitors of heme oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2). Some of these compounds were found to be good inhibitors of HO-1, in particular those carrying an imidazole moiety as azolyl group and a 3-bromo or 4-iodophenyl as aryl moiety. The most potent compounds 6 and 30 were selected and studied for their antitumor properties in a model of LAMA-84 R cell line overexpressing HO-1 and resistant to imatinib mesylate (IM), a tyrosine-kinase inhibitor used in the treatment of multiple types of cancer, most notably Philadelphia Chromosome positive (Ph(+)) Chronic Myelogenous Leukemia (CML). Results show that both 6 and 30 sensitized LAMA-84 R cell line to antitumor properties of IM.
European Journal of Medicinal Chemistry | 2015
Loredana Salerno; Valeria Pittalà; Giuseppe Romeo; Maria N. Modica; Agostino Marrazzo; Maria A. Siracusa; Valeria Sorrenti; Claudia Di Giacomo; Luca Vanella; Neha N. Parayath; Khaled Greish
Heme oxygenase (HO) is a cytoprotective enzyme that can be overexpressed in some pathological conditions, including certain cancers. In this work, novel imidazole derivatives were designed and synthesized as inhibitors of heme oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2). In these compounds the imidazole ring, crucial for the activity, is connected to a hydrophobic group, represented by aryloxy, benzothiazole, or benzoxazole moieties, by means of alkyl or thioalkyl chains of different length. Many of the tested compounds were potent and/or selective against one of the two isoforms of HO. Furthermore, most of the pentyl derivatives showed to be better inhibitors of HO-2 with respect to HO-1, revealing a critical role of the alkyl chain in discriminating between the two isoenzymes. Compounds which showed the better profile of HO inhibition were selected and tested to evaluate their cytotoxic properties in prostate and breast cancer cell lines (DU-145, PC3, LnCap, MDA-MB-231, and MCF-7). In these assays, aryloxyalkyl derivatives resulted more cytotoxic than benzothiazolethioalkyl ones; in particular compound 31 was active against all the cell lines tested, confirming the anti-proliferative properties of HO inhibitors and their potential use in the treatment of specific cancers.
Bioorganic & Medicinal Chemistry | 2010
Simona Bindi; Daniele Fancelli; Cristina Alli; Daniela Berta; Jay Aaron Bertrand; Alexander D. Cameron; Paolo Cappella; Patrizia Carpinelli; Giovanni Cervi; Valter Croci; Matteo D’Anello; Barbara Forte; M.Laura Giorgini; Aurelio Marsiglio; Juergen Moll; Enrico Pesenti; Valeria Pittalà; Maurizio Pulici; Federico Riccardi-Sirtori; Fulvia Roletto; Chiara Soncini; Paola Storici; Mario Varasi; Daniele Volpi; Paola Zugnoni; Paola Vianello
A novel series of 3-amino-1H-thieno[3,2-c]pyrazole derivatives demonstrating high potency in inhibiting Aurora kinases was developed. Here we describe the synthesis and a preliminary structure-activity relationship, which led to the discovery of a representative compound (38), which showed low nanomolar inhibitory activity in the anti-proliferation assay and was able to block the cell cycle in HCT-116 cell line. This compound demonstrated favorable pharmacokinetic properties and good efficacy in the HL-60 xenograft tumor model.
Chemical Biology & Drug Design | 2012
Valeria Sorrenti; Salvatore Guccione; Claudia Di Giacomo; Maria N. Modica; Valeria Pittalà; Rosaria Acquaviva; Livia Basile; Morena Pappalardo; Loredana Salerno
Imidazole‐based compounds previously synthesized in our laboratory were selected and reconsidered as inhibitors of heme oxygenase‐1 obtained from the microsomal fractions of rat spleens. Most of tested compounds were good inhibitors with IC50 values in the low micromolar range. Compounds were also assayed on membrane‐free full‐length recombinant human heme oxygenase‐1; all tested compounds were unable to interact with human heme oxygenase‐1 at 100 μm concentrations with the exception of compounds 11 and 13 that inhibited the enzyme of 54% and 20%, respectively. The binding of the most active compound 11 with heme or heme‐conjugated human heme oxygenase‐1 was also examined by spectral analyses. When heme was not conjugated to human heme oxygenase‐1, compound 11 caused changes in the heme spectrum only at concentration 50‐fold (100 μm) higher than that required to inhibit rat heme oxygenase‐1; when heme was conjugated to human heme oxygenase‐1, compound 11 was able to form a heme‐compound 11 complex also at low micromolar concentrations. To obtain information on the binding mode of the tested compounds with enzyme, docking studies and pharmacophore analysis were performed. Template docking results were in agreement with experimental inhibition data and with a structure‐based pharmacophoric model. These data may be exploitable to design new OH‐1 inhibitors.
European Journal of Medicinal Chemistry | 2012
Loredana Salerno; Maria N. Modica; Giuseppe Romeo; Valeria Pittalà; Maria A. Siracusa; Maria E. Amato; Rosaria Acquaviva; Claudia Di Giacomo; Valeria Sorrenti
We previously described a series of imidazole-based inhibitors substituted at N-1 with an arylethanone chain as interesting inhibitors of neuronal nitric oxide synthase (nNOS), endowed with good selectivity vs endothelial nitric oxide synthase (eNOS). As a follow up of these studies, several analogs characterized by the presence of substituted imidazoles or other mono or bicyclic nitrogen-containing heterocycles instead of simple imidazole were synthesized, and their biological evaluation as in vitro inhibitors of both nNOS and eNOS is described herein. Most of these compounds showed improved nNOS and eNOS inhibitory activity with respect to reference inhibitors. Selected compounds were also tested to analyze their antioxidant properties. Some of them displayed good capacity to scavenge free radicals and ability to reduce lipid peroxidation.
Journal of Cheminformatics | 2017
Giovanni Nastasi; Carla Miceli; Valeria Pittalà; Maria N. Modica; Orazio Prezzavento; Giuseppe Romeo; Antonio Rescifina; Agostino Marrazzo; Emanuele Amata
AbstractBackground Sigma (σ) receptors are accepted as a particular receptor class consisting of two subtypes: sigma-1 (σ1) and sigma-2 (σ2). The two receptor subtypes have specific drug actions, pharmacological profiles and molecular characteristics. The σ2 receptor is overexpressed in several tumor cell lines, and its ligands are currently under investigation for their role in tumor diagnosis and treatment. The σ2 receptor structure has not been disclosed, and researchers rely on σ2 receptor radioligand binding assay to understand the receptor’s pharmacological behavior and design new lead compounds.Description Here we present the sigma-2 Receptor Selective Ligands Database (S2RSLDB) a manually curated database of the σ2 receptor selective ligands containing more than 650 compounds. The database is built with chemical structure information, radioligand binding affinity data, computed physicochemical properties, and experimental radioligand binding procedures. The S2RSLDB is freely available online without account login and having a powerful search engine the user may build complex queries, sort tabulated results, generate color coded 2D and 3D graphs and download the data for additional screening.ConclusionThe collection here reported is extremely useful for the development of new ligands endowed of σ2 receptor affinity, selectivity, and appropriate physicochemical properties. The database will be updated yearly and in the near future, an online submission form will be available to help with keeping the database widely spread in the research community and continually updated. The database is available at http://www.researchdsf.unict.it/S2RSLDB.Graphical abstract
European Journal of Medicinal Chemistry | 2014
Loredana Salerno; Valeria Pittalà; Maria N. Modica; Maria A. Siracusa; Sebastiano Intagliata; Alfredo Cagnotto; Mario Salmona; Rafał Kurczab; Andrzej J. Bojarski; Giuseppe Romeo
A novel series of arylpiperazinylalkyl 2-benzoxazolones and 2-benzothiazolones 18-38 was designed, synthesized and tested to evaluate their affinity for the 5-HT7 and 5-HT1A receptors. Compounds with a 2-benzothiazolone nucleus generally had affinity values higher than the corresponding 2-benzoxazolone compounds. In particular, derivatives possessing a six or seven carbon chain linker between 2-benzothiazolone and arylpiperazine had Ki values in the subnanomolar range for the 5-HT1A receptor and in the low nanomolar range for the 5-HT7 receptor, indicating that they may be interesting dual ligands. Molecular modeling studies revealed different docking poses for the investigated compounds in homology models of 5-HT1A and 5-HT7 receptors, which explained their experimentally determined affinities and general low selectivity. Additionally, structural interaction fingerprints analysis identified the important amino acid residues for the specific interactions of long-chain arylpiperazines within the binding pockets of both serotonin receptors.
Bioorganic & Medicinal Chemistry | 2011
Valeria Pittalà; Maria A. Siracusa; Maria N. Modica; Loredana Salerno; Alessandro Pedretti; Giulio Vistoli; Alfredo Cagnotto; Tiziana Mennini; Giuseppe Romeo
Three different series of 1H-pyrrolopyrimidine-2,4-dione derivatives were designed and synthesized as ligands for the α(1)-adrenergic receptors (α(1)-ARs). A microwave-assisted protocol was developed in order to improve purity and yields of some final products. The majority of the synthesized compounds, tested in binding assays, displayed α(1)-AR affinities in the nanomolar range. Highest affinity values were found in derivatives 10b and 10c (K(i)=1.4 nM for both) whereas compound 10e was endowed with the best profile in term of α(1)-AR affinity (K(i)=2.71 nM) coupled with high selectivity towards 5-HT(1A) receptors (K(i) >10,000). Molecular docking studies were performed on human α(1)-ARs and human 5-HT(1A) receptors in order to rationalize the observed experimental affinity and selectivity; these computational studies helped to clarify molecular requirements for the design of high-selective α(1)-adrenergic ligands.